Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19

Druedahl, Louise C. ; Lebret, Audrey and Minssen, Timo LU (2020) In Journal of Law, Medicine & Ethics 48(3). p.579-582
Abstract
There is no doubt that COVID-19 will have a substantial impact on access to biologics and biosimilar uptake, as well as on the related ethical, legal, and social dimensions of prioritization decisions. This holds especially true for Denmark and European markets, where governments are expected to cover most of the pharmaceutical needs of their citizens and where the crisis has been leading to an important reduction of available resources. In this paper we make four key comments relating to (1) broader ethico-legal dimensions of prioritizations in Europe, (2) human rights law and (3) regulatory aspects of access, diversification, vulnerability and systemic trust, and (4) additional challenges posed by COVID-19.
Please use this url to cite or link to this publication:
author
; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Medical law, Medicinsk rätt
in
Journal of Law, Medicine & Ethics
volume
48
issue
3
pages
4 pages
publisher
SAGE Publications
external identifiers
  • scopus:85092356937
  • pmid:33021187
ISSN
1073-1105
DOI
10.1177/1073110520958884
project
The Quantum Law Project
language
English
LU publication?
no
id
6db777f6-50fe-427e-bce7-879889422a34
date added to LUP
2020-12-16 13:11:14
date last changed
2022-04-19 02:45:47
@article{6db777f6-50fe-427e-bce7-879889422a34,
  abstract     = {{There is no doubt that COVID-19 will have a substantial impact on access to biologics and biosimilar uptake, as well as on the related ethical, legal, and social dimensions of prioritization decisions. This holds especially true for Denmark and European markets, where governments are expected to cover most of the pharmaceutical needs of their citizens and where the crisis has been leading to an important reduction of available resources. In this paper we make four key comments relating to (1) broader ethico-legal dimensions of prioritizations in Europe, (2) human rights law and (3) regulatory aspects of access, diversification, vulnerability and systemic trust, and (4) additional challenges posed by COVID-19.}},
  author       = {{Druedahl, Louise C. and Lebret, Audrey and Minssen, Timo}},
  issn         = {{1073-1105}},
  keywords     = {{Medical law; Medicinsk rätt}},
  language     = {{eng}},
  month        = {{10}},
  number       = {{3}},
  pages        = {{579--582}},
  publisher    = {{SAGE Publications}},
  series       = {{Journal of Law, Medicine & Ethics}},
  title        = {{ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19}},
  url          = {{http://dx.doi.org/10.1177/1073110520958884}},
  doi          = {{10.1177/1073110520958884}},
  volume       = {{48}},
  year         = {{2020}},
}